Overview
- Mave Health raised $2.1 million in seed funding led by Blume Ventures, with participation from Stanford Angels and other investors.
- Mave makes a non-invasive wearable headset using transcranial direct current stimulation (tDCS) to support focus, mood and stress regulation in 20 minutes a day.
- The company completed a beta with over 500 customers ahead of its public release.
The News
San Francisco-based Mave announced the round in March 2026. It reported self-reported beta results after four weeks of use, including an average mood improvement of 77%.
CEO Dhawal Jain said modern life constantly overloads the brain without giving it needed support.
Industry Perspective
Consumer neurotech is moving from labs to lifestyle products sold outside medical regulation. Self-reported outcomes are a weak basis for health claims.
Strategic Impact
Investor interest in at-home brain stimulation is rising, but controlled studies will be needed to separate real effects from placebo and earn clinician trust.
Source: Businesswire
